Coronary Stents

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

· 292 pages   · 61 Exhibits   · 78 Company Profiles   · Report #C245   · Published May 2009

This report details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease.  The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. 

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market.  The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction.  The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World.  The report provides competitor market shares by these geographic regions.  The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The global market for coronary stents is analyzed in this report as it contributes to the aggregate market for treatment of coronary artery disease, which includes surgical and interventional procedures and drugs, devices and other treatment options alone or in combination. The overall "map" of coronary artery disease treatment is illustrated below.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1:   CLINICAL BACKGROUND

1.1       Cardiovascular Disorders Applicable for Stent Implantation

1.1.1    Acute Closure

1.1.2    Restenosis After Angioplasty

1.2       Risk Factors for Coronary Heart Disease

1.3       Stenting vs. CABG and Angioplasty

1.4       Alternative Therapies for Coronary Atherosclerosis

1.4.1    Angioplasty With or Without Stenting

1.4.2    Atherectomy

1.4.3    Coronary Artery Bypass Graft (CABG)

1.4.3.1 Open CABG

1.4.3.2 Off-Pump Coronary Artery Bypass (OPCAB)

1.4.3.3 MIDCAB (Minimally Invasive Direct Coronary Bypass)

1.4.3.4 RACAB (Robotic Assisted Coronary Artery Bypass)

1.4.3.5 Other Forms of CABG

1.4.4    Transmyocardial Laser Revascularization (TMR)

1.4.5    Genetic Therapies

1.4.6    HDL Therapy

1.4.7    Drug-Eluting Balloons

1.4.8    Nanoparticles and Other Agents

1.5       Incidence and Prevalence of Cardiovascular Stenting Procedures

1.6       Complications Related to Cardiovascular Stents

SECTION 2:   PRODUCTS, TECHNOLOGIES

2.1       Materials Used in Cardiovascular Stents

2.2       Various Stent Shapes and Resulting Impact

2.3       FDA Approval of Cardiovascular Stents

2.4       Reimbursement of Drug-Eluting Stents

2.5       Bare Metal Stents

2.6       Drug-Eluting Stents

2.6.1    Abbott Vascular

2.6.2    Boston Scientific

2.6.3    Johnson & Johnson/Cordis

2.6.4    Medtronic

2.6.5    Other Drug-Eluting Stent Companies

2.7       Bioabsorbable Stents

2.8       Other Types of Stents

2.9       Legal Proceedings

2.10     Key Clinical Trials

2.10.1  HORIZONS AMI

2.10.2  SYNTAX

2.10.3  SPIRIT

2.10.4  COURAGE

2.10.5  PROTECT

2.10.6  ENDEAVOR

2.10.7  FAME

2.10.8  SORT OUT III

2.10.9  DAPT

2.10.10  ZEST

SECTION 3:   MARKETS FORECASTS AND COMPETITOR SHARES

3.1       Worldwide Market for Coronary Stents

3.1.1    Worldwide Market for Drug-Eluting Coronary Stents

3.1.2    Worldwide Market for Bare Metal Coronary Stents

3.1.3    Worldwide Market for Absorbable Coronary Stents

3.2       U.S. Market for Coronary Stents

3.2.1    U.S. Market for Drug-Eluting Coronary Stents

3.2.2    U.S. Market for Bare Metal Coronary Stents

3.2.3    U.S. Market for Absorbable Coronary Stents

3.3       European Market for Coronary Stents

3.3.1    European Market for Drug-Eluting Coronary Stents

3.3.2    European Market for Bare Metal Coronary Stents

3.3.3    European Market for Absorbable Coronary Stents

3.4       Asia/Pacific Market for Coronary Stents

3.4.1    Asia/Pacific Market for Drug-Eluting Coronary Stents

3.4.2    Asia/Pacific Market for Bare Metal Coronary Stents

3.4.3    Asia/Pacific Market for Absorbable Coronary Stents

3.5       Rest of World (ROW) Market for Coronary Stents

3.5.1    ROW Market for Drug-Eluting Coronary Stents

3.5.2    ROW Market for Bare Metal Coronary Stents

3.5.3    ROW Market for Absorbable Coronary Stents

SECTION 4:   COMPANY PROFILES

4.1       Aachen Resonance GmbH

4.2       Abbott Vascular

4.3       AdvanSource Biomaterials Corporation

4.4       Aeon Bioscience

4.5       Allvivo Vascular, Inc.

4.6       Amaranth Medical, Inc.

4.7       amg International GmbH

4.8       Arterial Remodeling Technologies (ART)

4.9       Arterius Ltd.

4.10       Atrium Medical

4.11       Avantec Vascular

4.12       B. Braun Melsungen

4.13       Balton Ltd.

4.14       Bioabsorbable Therapeutics, Inc.

4.15       Bioring SA

4.16       Biosensors International

4.17       Biotronik

4.18       Blue Medical Devices B.V.

4.19       Boston Scientific

4.20       Caliber Therapeutics

4.21       Cappella Inc.

4.22       CardioMind, Inc.

4.23       CeloNova BioSciences, Inc.

4.24       CID S.r.l. (Formerly Sorin Vascular Therapy)

4.25       Cinvention AG (Formerly Blue Membranes)

4.26       CorNova

4.27       CV Therapeutics/Gilead Inc.

4.28       Devax

4.29       DISA Vascular

4.30       Elixir Medical Corp.

4.31       Estracure Inc.

4.32       eucatech AG

4.33       Genesis Technologies, LLC

4.34       Global Therapeutics (Cook Medical)

4.35       Hexacath

4.36       ICON Interventional (Formerly ICON Medical Corp.)

4.37       InspireMD

4.38       InTek Technology

4.39       Invatec s.r.l.

4.40       ITGI Medical Ltd.

4.41       Johnson & Johnson

4.41.1       Cordis

4.41.2       Conor Medsystems (J&J)

4.42       JW Medical Systems / Biosensors International

4.43       Kaneka Corporation

4.44       Kyoto Medical Planning Co., Ltd.

4.45       Lepu Medical

4.46       Lutonix, Inc.

4.47       Medinol/ARIAD Pharmaceuticals

4.48       Medlogics Device Corporation (MDC)

4.49       Medtronic Vascular

4.50       Miami Cardiovascular Innovations

4.51       Micell Technologies

4.52       MicroPort Scientific Corporation

4.53       Minvasys

4.54       MIV Therapeutics

4.55       mNEMOSCIENCE GmbH

4.56       MoBeta, Inc.

4.57       NanoInterventions, LLC

4.58       Neovasc, Inc.

4.59       Nexeon MedSystems, Inc.

4.60       Opto Circuits (India) Ltd.

4.60.1       EuroCor GmbH

4.61       OrbusNeich

4.62       Palmaz Scientific, Inc.

4.63       Picarus NV

4.64       Possis Medical (Bayer)

4.65       Prescient Medical

4.66       Relisys Medical Devices

4.67       REVA Medical

4.68       Sahajanand Medical Technologies

4.69       Stentys SAS

4.70       Sterling Vascular

4.71       Terumo

4.72       Translumina

4.73       TriReme Medical

4.74       Tryton Medical

4.75       Vascular Concepts

4.76       VasoTech, Inc.

4.77       X-Cell Medical

4.78       Xtent, Inc. (August 3, 2009: Xtent shareholders approve plan to dissolve and liquidate company after it is unable to raise the necessary funds to continue its stent development.)

APPENDIX I:  SELECTED CLINICAL TRIALS

ABSORB

ARRIVE II Registry

ARTS

AXXESS PLUS

BASKET

BBC ONE

CARE

COREL

COSTAR

COURAGE

CUSTOM

DEScover Registry

DIRECT

DIVERGE

e-HEALING

EASTER Registry

ENDEAVOR

ETHOS

EuroSTAR

EVENT Registry

FAME

GENESIS

FOCUS

HEALING

HORIZONS-AMI

ISAR, ISAR-TEST-2

LONG DES

NOBLESS

NOBORI

NORDIC

OLYMPIA Registry

PASSION

PREPARE

PROGRESS

RESOLUTE

RESORB

REWARD Registries

SERIES

SIMPLE Registries

SIRIUS, E-SIRIUS, C-SIRIUS

SORT-OUT III

SPIRIT

STEALTH

STEMI

STENT Registry

SVELT

TAXUS

TYPHOON

ZEST-AMI

ZOMAXX

APPENDIX II:  COMPANY DIRECTORY

List of Exhibits

Exhibit ES-1: Types of Cardiovascular Disease and Incidence in the United States, 2006

Exhibit ES-2: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States

Exhibit ES-3: Potential Complications Related to Implantation of Cardiovascular Stents

Exhibit ES-4: Types of Coronary Stents and Selected Anti-Restenosis Devices

Exhibit ES-5: Worldwide DES Market by Company, Calendar 4th Quarter, 2008

Exhibit ES-6: Worldwide Market for Coronary Stents, by Type, Revenue Forecast, 2008–2017

Exhibit ES-7: Worldwide Market for Drug-Eluting Coronary Stents, by Region, Revenue Forecast, 2008–2017

Exhibit ES-8: Worldwide Market for Bare Metal Coronary Stents, by Region, Revenue Forecast, 2008–2017

Exhibit ES-9: Worldwide Market for Absorbable Coronary Stents, by Region, Revenue, 2012–2017

Exhibit 1-1: Types of Cardiovascular Disease and Incidence in the United States, 2006

Exhibit 1-2: International Death Rates Per 100,000 Population for Total Cardiovascular Disease and Coronary Heart Disease for the Top 20 Countries

Exhibit 1-3: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States

Exhibit 1-4: Drug-Eluting Balloon Catheters

Exhibit 1-5: Estimated Inpatient Cardiovascular Procedures, U.S., 2006 (000)

Exhibit 1-6: Number of Discharges, Coronary Atherosclerosis, U.S.

Exhibit 1-7: National Healthcare Cost and Utilization Project Statistics: Mean Charges and In-Hospital Death Rates for Various Cardiovascular Procedures, U.S.

Exhibit 1-8: Total Number of Cardiac Revascularization Discharges and Mean Charges, U.S., 1993–2006

Exhibit 1-9: Total Number of Discharges for PCI Procedures with Non-Drug-Eluting Stents and Mean Charges, U.S., 2002–2006

Exhibit 1-10: Total Number of Discharges for PCI Procedures with Drug-Eluting Stents and Mean Charges, U.S., 2002–2006

Exhibit 1-11: Total Number of Discharges for PCI Procedures with Non-Drug and Drug-Eluting Stent Discharges and Mean Charges, U.S., 2002–2006

Exhibit 2-1: Competitors in the Market for Bare Metal Stents

Exhibit 2-2: Competitors in the Market for Drug-Eluting Stents

Exhibit 2-3: Competitors in the Market for Bioresorbable Stents

Exhibit 2-4: Competitors in the Market for Novel Stent Technologies

Exhibit 3-1: Worldwide Coronary Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-2: Worldwide Drug-Eluting Coronary Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-3: Revenues for Leading Drug-Eluting Stent Market Competitors, Worldwide, 2008

Exhibit 3-4: Worldwide Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-5: Worldwide Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017

Exhibit 3-6: U.S. Market for Coronary Stents, by Type, Revenue Forecast, 2008-2017

Exhibit 3-7: U.S. Coronary Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-8: Revenues for Leading Drug-Eluting Stent Market Competitors, United States, 2008

Exhibit 3-9: U.S. Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-10: U.S. Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017

Exhibit 3-11: European Coronary Stent Market, by Type, Revenue Forecast, 2008-2017

Exhibit 3-12: European Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-13: European Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-14: European Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017

Exhibit 3-15: Asia/Pacific Market Forecasts for Coronary Stents, by Type, Revenue Forecast, 2008-2017

Exhibit 3-16: Asia/Pacific Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-17: Asia/Pacific Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-18: Asia/Pacific Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017

Exhibit 3-19: Rest of World Coronary Stent Market, by Type, Revenue Forecast 2008-2017

Exhibit 3-20: Rest of World Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-21: Rest of World Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017

Exhibit 3-22: Rest of World Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017

Exhibit 4-1: AdvanSource Biomaterials Third Quarter Financial Results ($000s)

Exhibit 4-2: Medtronic Financial Data, Third Quarter 2009 ($millions)

Exhibit 4-3: Medtronic’s Coronary Stent Revenues, FY 2008 & 2009 ($millions)

Exhibit 4-4: Xtent Financial Data, Fourth-Quarter 2008 ($millions)

Request a report sample by emailing request to:

 

---

 

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents,  2008-2017

May 2009

 

Price:  $1,950 (print or PDF; add $200 for both).  Site/Global license also available.

Purchase for immediate PDF download via online store (PDF and other options also below) or fax us your order form..

REPORT: Worldwide Coronary Stents 2009, PDF -- $1,950.00   REPORT: Worldwide Coronary Stents 2009, Print -- $1,950.00   REPORT: Worldwide Coronary Stents 2009, Print & PDF -- $2,150.00   REPORT: Worldwide Coronary Stents 2009, Site License -- $3,450.00   REPORT: Worldwide Coronary Stents 2009, Global License -- $4,450.00

For more info:

Patrick Driscoll tel:  +1.949.859.3401 tel:  +1.949.891.1753 (google voice)

Methodology. MedMarket Diligence Reports are produced through primary and secondary research. Primary research includes interviews with clinicians and industry representatives for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary research includes gathering data from published sources (annual reports, Securities and Exchange Commission 10K, 10Q and other regulatory filings, federal/state/international datasets, company literature, others) on products and technologies on the market and under development. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

 

 Contact: Patrick Driscoll, (949) 859-3401. patrick<at>mediligence<dot>com.

Copyright © 2009 MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

Or call
+1.949.891.1753
+1.949.859.3401
+1.949.837.4558 fax

advanced medical technologies (blog)

Follow us on Twitter Follow medmarket

MedMarket Diligence Reports Coverage

• NEW: Wound Management 2012

• NEW: Spine Surgery Data Forecast

• Sealants/Glues 2012

• Spine Surgery 2011

• Obesity Management 2011

• Diabetes Management 2010

• Ablation Technologies 2010
  
• Tissue Engineering & Cell Therapy 2010

• Wound Management 2009

• Worldwide Coronary Stents

• Orthopedic Biomaterials

• Ophthalmology

• Micro / Nanomedicine

• Bone Graft Substitutes

Contact Us